EpiCept Corporation To Present At The Rodman & Renshaw 3rd Annual Global Healthcare Conference

ENGLEWOOD CLIFFS, N.J., May 11 /PRNewswire-FirstCall/ -- EpiCept Corporation today announced that Jack Talley, CEO, will be presenting at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Monday, May 15, 2006 at 11:55 a.m. CEST/5:55 a.m. EDT at Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco. Mr. Talley will present a company overview.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) The presentation will be webcast live at: http://wsw.com/webcast/rrshq8/epct/ A replay of the webcast presentation will be available for 90 days. About EpiCept Corporation

EpiCept is a specialty pharmaceutical company that focuses on fulfilling unmet needs in the treatment of pain and cancer. The company has a staged portfolio with several pain therapies in late-stage clinical trials and a lead oncology compound (for AML) with demonstrated efficacy in a Phase III trial that is intended for commercialization in Europe. EpiCept is based in New Jersey, and the company's research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 that speak only as of the date hereof and involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of the Company's respective product candidates, the conduct and results of future clinical trials, and plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that EpiCept will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in EpiCept's periodic reports and other filings with the SEC.


Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comEpiCept Corporation

CONTACT: Robert W. Cook of EpiCept Corporation, +1-201-894-8980,rcook@epicept.com; or Francesca T. DeVellis of Feinstein Kean Healthcare,+1-617-577-8110, francesca.devellis@fkhealth.com

Back to news